logo
AB-PMJAY, Jan Aushadhi Kendras boosting healthcare for middle class in last 11 years

AB-PMJAY, Jan Aushadhi Kendras boosting healthcare for middle class in last 11 years

Hans Indiaa day ago

New Delhi: Flagship scheme like the Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) and the Jan Aushadhi Kendras under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) has significantly enhanced healthcare for middle class in the last 11 years, according to an official statement issued on Thursday.
'Healthcare in India has seen a quiet but far-reaching shift in the last eleven years. Through a blend of targeted public schemes and digital reach, the Government has made quality healthcare both affordable and accessible for millions, especially the middle class,' the statement said.
With more than 41.02 crore Ayushman Cards created in 33 States and Union Territories, as of May 30, AB-PMJAY has emerged as one of the world's largest publicly funded health assurance schemes.
The scheme has enabled 8.59 crore hospital admissions worth Rs 1,19,858 crore, ensuring access to secondary and tertiary care without pushing families into debt, the statement said.
Further, with the number of Jan Aushadhi Kendras rising to 16,469, as of May 30, from just 80 in 2014, the PMBJP brought essential medicines within reach of the common citizen.
These outlets offer medicines that cost 50 to 80 per cent less than branded options, with strict quality standards ensured through WHO-GMP certified suppliers.
The scheme serves around 10 to 12 lakh people daily, and cumulative savings over the last eleven years are estimated to be more than Rs 38,000 crore, the statement said.
The product range now includes 2,110 medicines, including for chronic conditions like diabetes or heart disease, and 315 surgical products, covering all major treatments, cutting down financial stress for millions of families, especially the middle class.
'From free hospitalisation for senior citizens to low-cost medicines available nationwide, people today have better control over their health expenses. The digital backbone supporting these schemes has made enrolment, access, and tracking easier than ever. This change has allowed the middle class to benefit from savings on medicines, timely treatment, and greater medical security without bureaucratic hassles,' the statement said.
'Over the past eleven years, the government has shown unwavering commitment to uplifting the middle class in meaningful ways. The policies and reforms introduced have not only eased everyday challenges but also strengthened financial security, housing, healthcare, and skill development,' it added.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Poinguinim boar attack victim compensated
Poinguinim boar attack victim compensated

Time of India

time2 hours ago

  • Time of India

Poinguinim boar attack victim compensated

Canacona: The forest department paid a compensation of Rs 85,000 to Jayanti Velip, who developed deformities from a wild boar attack in Jan. The compensation papers were prepared by the assistant conservator of forests (South) Harsh Phadte and range forest officer, Canacona, Anant Velip, under the supervision of the deputy conservator of forests (South), Satish Kumar Reddy. Velip was working in a paddy field at Velwada, Poinguinim when a wild boar attacked her from behind. She fought with the boar and suffered injuries, resulting in 82% disability to her thumb and ear, she told TOI . After the attack, she was hospitalised for over two months and is now unable to use her right thumb or hear properly with her one ear. Get the latest lifestyle updates on Times of India, along with Eid wishes , messages , and quotes !

Indian pharma market grows 7.2% in May led by chronic therapies
Indian pharma market grows 7.2% in May led by chronic therapies

Business Standard

time3 hours ago

  • Business Standard

Indian pharma market grows 7.2% in May led by chronic therapies

Indian pharma market grew 7.2% in May with strong performance in chronic therapies such as cardiac and anti-infectives, along with gains from price hikes and new launches Sanket Koul New Delhi The Indian Pharma Market (IPM) grew 7.2 per cent in May this year with almost all major therapies showing positive growth, according to market research firm Pharmarack. Data suggest that big chronic therapies such as cardiac and anti-infectives, which account for nearly 25 per cent of the overall domestic market, recorded value growth of 11.7 per cent and 7.6 per cent, respectively. On the other hand, several smaller supergroups such as urology and antineoplastics, which made up 2 per cent each of the IPM's sales value for the month, also recorded double-digit growth in May at 12.3 per cent and 11.7 per cent, said Sheetal Sapale, vice-president, commercial, Pharmarack. Data suggest that the overall value growth for the IPM in May was driven by price growth and new introductions. The IPM also reported a minuscule 0.4 per cent unit growth during the month, with the chronic segments such as antidiabetics (6.1 per cent) and cardiac (4.8 per cent) performing better than the overall market figure. Experts believe that the antidiabetic segment saw a 6.1 per cent rise in volume in May due to a key drug, empagliflozin, going off-patent, as companies launched several plain and combination medications in the segment. Growth in the moving annual turnover (MAT) for the IPM between June 2024 and May 2025 stood at 8.1 per cent, leading to a total turnover of over Rs 2.29 trillion, while volumes in the domestic market grew by 1.1 per cent. The MAT of leading therapy areas such as cardiac, gastrointestinal and anti-infectives, which constitute around 38 per cent of the pharmaceutical market, showed robust volume growth at 10.4 per cent, 9.5 per cent and 6.5 per cent, respectively. While the top 20 brands in the IPM registered modest monthly value growth in the domestic market during the month, Sun Pharma and Dr Reddy's posted significant monthly value growth at 11.2 per cent each. They were followed by Torrent Pharma and Ipca Laboratories at 10.8 per cent, and Alkem Laboratories at 10.3 per cent monthly value growth. According to Pharmarack data, GlaxoSmithKline's (GSK) antibiotic medication Augmentin and USV's anti-diabetic drug Glycomet GP continued to be the top-selling medicine brands at the MAT level, with sales worth Rs 819 crore and Rs 810 crore, respectively.

FDA shuts 3 food businesses at Patradevi, Margao
FDA shuts 3 food businesses at Patradevi, Margao

Time of India

time4 hours ago

  • Time of India

FDA shuts 3 food businesses at Patradevi, Margao

Panaji: The food and drugs administration (FDA) directed two food business operators—a restaurant and a cashew shop—to suspend operations at Patradevi, Pernem, due to unhygienic conditions. The FDA inspected 18 outlets at Patradevi, issued improvement notices, and gave them 14 days to comply. They seized Rs 50,000 worth of food items, including chips, chocolates, and dry fruits with artificial colours. Samples of sweets were also taken for testing. The FDA also directed a restaurant in Margao to shut down for failing to pay a fine and for non-compliance with FDA directions following its inspection on April 28. They found that only 5 of 30 deficiencies were addressed and ordered the food operator to stop all activities and submit a compliance report. Get the latest lifestyle updates on Times of India, along with Eid wishes , messages , and quotes !

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store